drugset
drugset / Trial / NCT00613327

An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants

NCT00613327 ↗

Phase 4 Completed 345 enrolled Janssen Korea, Ltd., Korea
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the efficacy of oxybutynin chloride oral osmotic therapeutic system (OROS) on patient-reported outcomes after 12 weeks of treatment by dose escalation in participants with overactive bladder.

Timeline

Start
2007-09
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxybutynin Small molecule 10 mg Oral
Subject Oxybutynin Small molecule 20 mg Oral
Subject Oxybutynin Small molecule 30 mg Oral

Indications

overactive bladder